Home › Duchenne Muscular Dystrophy › NCT06839469

Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders

Who can join

Ages 5 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Genetic confirmation of disease (DMD, SMA) or healthy control
* Able to walk independently at least 25 meters
* Ongoing corticosteroids therapy or initiation of corticosteroid therapy in the previous 3 months for DMD
* Stable dose of FDA approved SMN up-regulator therapy or in an open-label extension phase of a study treatment for at least 6 months for SMA or gene replacement at enrollment for SMA or DMD participants.

Exclusion Criteria:

* Use foot orthoses or assistive devices for community ambulation or a mobility device for community navigation
* Use investigational medications intended for treatment of NMD within 30 days
* Prior to study entry had an injury or surgery that would impact gait within the previous 3 months

About the study

The purpose of this research is (1) to identify disease specific walking-related digital biomarkers of disease severity, and (2) monitor longitudinal changes in natural environments, for extended periods of time, in DMD and SMA.

Sponsor: Columbia University · Participants: 106 · Started: May 1, 2024

Contact the study team

• Jacqueline Montes, PT, EdD · Phone: 212-305-8916
• Cara Kanner, DPT · Phone: 516-581-8150

Official record on ClinicalTrials.gov — NCT06839469

Locations in the U.S.

Conditions

• Duchenne Muscular Dystrophy
• Spinal Muscular Atrophy
• Neuromuscular Disorders

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.